Nintedanib falls under the small molecule tyrosine-kinase inhibitor, targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor and platelet derived growth factor receptor.
On 15'th October 2014, US Food and Drug Administration granted the approval to this small molecule tyrosine-kinase inhibitor in order to treat idiopathic pulmonary fibrosis, and got a positive perspective from the EMA on 20'th November 2014, being approved in the European Union in the month of January, 2015.
In June 2011 until 15 October 2021, the US Food and Drug Administration granted the orphan drug designation to Nintedanib in order to treat idiopathic pulmonary fibrosis.
In the year of 2014, in European Union, this medication (nintedanib) was approved as a combination therapy in order to treat NSCLC, and is approved for this indication in certain other regions of the world.
In July 2016 until 6 September 2019, the US FDA granted orphan drug designation to nintedanib in order to treat systemic sclerosis (including the associated interstitial lung disease).
Nintedanib was granted priority review designation by the Food and Drug Administration prior to being approved in the United States on 6'th September 2019, in order to slow the rate of decline in pulmonary function in patients with SSc-ILD (systemic sclerosis associated interstitial lung disease). It is specifically the first FDA-approved treatment for this rare lung condition.
The US FDA granted priority review designation to nintedanib as well as breakthrough therapy designation. The Food and Drug Administration granted the approval of Ofev (Nintedanib) to Boehringer Ingelheim Pharmaceuticals, Inc.
The nintedanib 150 mg price is around 25,985 INR for a supply of 10 capsules, depending on the pharmacy/wholesaler you visit. Any WHO-GDP & ISO certified pharmaceutical wholesaler company would be best to buy nintedanib.
Source:-
https://diseaseandmedications.weebly.com/blog/history-of-nintedanib
Sign in to leave a comment.